APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Singapore Startups
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    Editor's Pick (1 - 4 of 8)
    left
    Rising biotech innovations to address Indonesia's healthcare problems

    Avina Sugiarto, Partner, East Ventures

    Evolving The Digital Wave in the Start-up Space

    Jeremy Loh, Co-Founder And Managing Partner, Genesis Alternative Ventures

    Singapore - Best Gateway to Investing in Asia

    Amra Naidoo, Co-founder & General Partner at Accelerating Asia

    Asia Is Hungry for Alternative Protein

    Nick Cooney, Founder, Managing Partner at Lever VC

    Smart Urbanism and an All-Digital Economy as Necessity, Not a Futuristic Dream

    Benson Tam, Founding Partner and Chairman, Venturous Group

    How to Cope with Covid19 Market Meltdown

    Patricia Poon, Founder & Managing Partner, Belmond Capital Limited

    How to Successfully Pitch Your Idea to a VC

    Vikas Datt, Managing Director and Partner at CerraCap Ventures

    Fintech, the Omnipresent

    Mark Munoz,Managing Partner, Vectr Fintech.

    right

    The Tide has Risen

    Dr. Dan Liu, Partner, CDH Investments

    Tweet
    content-image

    Dr. Dan Liu, Partner, CDH Investments

    The nearly two years’ epidemic, still wiping over major countries, urges innovations to be realized in weeks and months, rather than in multiple struggling years. The instant focus on biotechnologies like mRNA vaccines and POCT diagnostics pushes Life Sciences and Healthcare industries in China to blossom, and enterprises seize this moment to transfer decades of scientific research and investment into fruitful achievements. For only the first half of 2021, the fundraising amount for the Chinese Healthcare private market has expanded to around $15 billion. As an investor transitioned from a scientist, a Business Development (BD) management, and a consultant, I feel privileged to be an observer and a participant of this biotech blossom.

    Policies also contribute. On September 3rd, top officials of the China Securities Regulatory Commission (CSRC) made it clear that “the forthcoming Beijing Stock Exchange shall be tailor-made for the small- and medium-size, innovative companies”. The cruises will leverage over those aircraft carriers listed in Shanghai and Shenzhen. Nonetheless, a cruise always calls for leadership and execution. High-profile managements from multinational corporates (MNCs), current or former, along with scientists and investors, echo the tide to stream into the domestic industry.

    The first wave of top teams has migrated since around 2014-2016 to found biotech start-ups in China, concentrating on license-in strategies accompanied with independent research and development (R&D). The leaders usually held senior management positions in MNCs and even ran the subsidiary. Dr. Zang, who founded I-Mab in 2016 (the company listed on Nasdaq in 2020), had acted as the global senior vice president in GSK and head of GSK’s R&D Department in China.

    Dr. Wang, who founded Harbour BioMed in the same year (the company went public in Hongkong in 2020), had been Head of China R&D and of Translational Medicine, Asia Pacific, for Sanofi.

    Unlike their predecessors, the founders of the second start-up wave in around 2017-2019 established careers both in MNCs and in domestic pharma, pivoting from in-depth research to senior management, which equipped them with independent pipelines and proper license-out strategies to maximum sustainable operation and expansion. Dr. Lv, before founding GenFleet in 2017, worked at Wyeth and Novartis in America, then led R&D programs and provided strategic prospective in WuXi AppTec, Yangtze River, Gloria, and CStone Pharmaceuticals. Most recently, Innovent and GenFleet announced one of the largest deals between Chinese biotechs, the exclusive global License Agreement for GFH925, a novel KRAS-G12C Inhibitor, with a total package of up to $240 million. Dr. Wang from TechnoDerma chose his path to develop new drugs in dermatology after his years with OSI, Pfizer, AstraZeneca in the U.S., and then Viva Biotech in China. Currently, the company’s first compound for seborrheic alopecia (SA) is undergoing a Phase I clinical trial in America this year. The company also licensed-out this home-made privilege to a local biotech.

    The instant focus on biotechnologies like mrna vaccines and poct diagnostics pushes life sciences and healthcare industries in china to blossom, and enterprises seize this moment to transfer decades of scientific research and investment into fruitful achievements

    Academia and institutional researchers are noticed to pioneer in true fundamental innovations as well. Since 2020, top scientists, researchers and professors started to co-found start-up biotechs with professional executives, and sometimes, with investors together. This mode may look familiar to what US dollar funds does in Boston or Silicon Valley. Dr. Jia, Director of gene therapy and virus vector laboratory and Tenured associate professor of neurosurgery at University of British Columbia (UBC), explores new therapeutics on Transcription and Translation Dual Regulated (TTDR) oncolytic virus platform with his co-founded company Virogin Biotech. The target, oncolytic virus, has been a hit in the last two years as a cure for cancer (especially cold tumors), and the technique has been proven cutting-edge in global and effective in clinical trials. The hybrid of leading scientists and entrepreneurs puts Virogin under the spotlight of oncolytic virus drug development worldwide.

    These three waves are now leading the fast and gigantic tide of innovation. With the strong belief that the top talents from overseas can prosper in China as well as prosper China, the remaining question is, do Chinese biotech companies have an edge over Western counterparts in the future? If so, when?

    tag

    Life Sciences

    Securities

    Weekly Brief

    loading
    Top 10 Singapore Startups - 2022
    ON THE DECK

    Singapore Startups 2022

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    From Code To Impact: Leading Enterprise Ai With Purpose

    From Code To Impact: Leading Enterprise Ai With Purpose

    Jingting Cher, Deputy Director, Data Science, Sp Group
    Reimagining Pension Services Through Responsible Innovation

    Reimagining Pension Services Through Responsible Innovation

    Maz Mirza, Chief Digital Officer, KWAP Malaysia
    Maritime: Beyond Systems, Beyond Seas

    Maritime: Beyond Systems, Beyond Seas

    Ron Fong, Cio, Station Satcom
    Human-Centered Innovation in the GenAI Era

    Human-Centered Innovation in the GenAI Era

    CJ Meadows, Head of Innovation-Asia, Executive Education Designer, Professor & Head of Mbaconsulting, S P Jain School Of Global Management
    The Art and Science of Selling

    The Art and Science of Selling

    Scott White, Senior Manager Sales and Marketing Operations, Airbus
    Responsible Data Leadership in an AI-Driven World

    Responsible Data Leadership in an AI-Driven World

    Gemma Dias, Head of Data Governance, Tyro Payments
    Driving Guest-Centric IT Innovation in Integrated Resorts

    Driving Guest-Centric IT Innovation in Integrated Resorts

    Ching Yip, Vice President of Information Technology, Hoiana Resort & Golf
    Microsoft-Covering People 360 Degrees...

    Microsoft-Covering People 360 Degrees...

    Khalid Nizami , Heads The Digital Transformation Center Of Excellence For Asia Pacific, Ecolab
    Loading...
    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://singapore-startups.apacciooutlook.com/cxoinsights/the-tide-has-risen-nwid-9290.html